Author

L. Sisk-Hackworth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:metagenomics· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

E. C. Stites· 2 shared T. McFall· 2 shared A. A. Levine· 1 shared A. Nguyen· 1 shared A. Ramesh· 1 shared A. S. Shaw· 1 shared E. T. Kelley-Thackray· 1 shared J. Brown· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. C. Stites

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Hypogonadal (Gnrh1hpg) mice reveal niche-specific influence of reproductive axis and sex on intestinal microbial communities

L. Sisk-Hackworth, J. Brown, L. Sau, A. A. Levine, L. Y. I. Tam, A. Ramesh, R. S. Shah, E. T. Kelley-Thackray, S. Wang, A. Nguyen, S. T. Kelley, V. G. Thackray

This study uses hypogonadal mice to show sex and reproductive axis effects on intestinal microbial communities, with sex chromosomes also playing a role, and highlights limitations of fecal samples in reflecting small intestine diversity.

bioRxiv · Jun 20, 2023 · PreprintMicrobiology

Inhibition of both mutant and wild-type RAS-GTP in KRAS G12C colorectal cancer through cotreatment with G12C and EGFR inhibitors

T. McFall, M. Trogdon, L. Sisk-Hackworth, E. C. Stites

The paper shows that combining KRAS G12C and EGFR inhibitors inhibits both mutant and wild-type RAS, explaining their effectiveness in colorectal cancer.

bioRxiv · Oct 7, 2021Cancer Biology

A Systems Mechanism for KRAS Mutant Allele Specific Responses to Targeted Therapy

T. McFall, J. K. Diedrich, M. Mengistu, S. L. Littlechild, K. V. Paskvan, L. Sisk-Hackworth, J. J. Moresco, A. S. Shaw, E. C. Stites

The paper investigates why KRAS G13D mutant colorectal cancers respond to anti-EGFR therapy despite general resistance, using computational models and experimental validation.

bioRxiv · Dec 10, 2018Cancer Biology